Medication Options for Treatment of Stimulant Use Disorders: Optimistic Update and New Research

Overdose deaths associated with illicit stimulants (cocaine and methamphetamine) have surged in the past eight years, according to a recent study by the National Institutes for Health (NIH). While there are currently no FDA-approved medications for the treatment of individuals who are dependent on stimulants, new treatments utilizing readily available medications are showing encouraging empirical support.

Join us Tuesday, March 2, at 1 p.m. ET, for “Medication Options for Treatment of Stimulant Use Disorders: Optimistic Update and New Research,” when we’ll examine the latest groundbreaking research in the context of current increases in stimulant use. Marc Fishman, MD, medical director of Maryland Treatment Centers, a member of the psychiatry faculty of the Johns Hopkins University School of Medicine, and a member of the National Council’s Medical Director Institute will share his expertise as an addiction medicine specialist to bring the latest information to help you:

• Understand the current epidemiology of stimulant use in the U.S.
• Address the most common clinical challenges in treating people with stimulant use disorders.
• Explore new research that provides evidence for potential treatment of stimulant use disorder treatment.

• RSVP